Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Eugene R. Bleecker, Michael E. Wechsler, J. Mark FitzGerald, Andrew Menzies-Gow, Yanping Wu, Ian Hirsch, Mitchell Goldman, Paul Newbold, James G. Zangrilli

Source: Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018
Journal Issue: October
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Eugene R. Bleecker, Michael E. Wechsler, J. Mark FitzGerald, Andrew Menzies-Gow, Yanping Wu, Ian Hirsch, Mitchell Goldman, Paul Newbold, James G. Zangrilli. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Baseline characteristics of severe asthma patients initiating biologic treatment worldwide
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021


Effects of exacerbation risk on symptoms and clinical characteristics in patients with bronchiectasis
Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation
Year: 2012

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma
Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021
Year: 2021



Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019


Patient baseline variables predict future asthma control status and risk of exacerbations
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials
Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019
Year: 2019



Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
Source: Eur Respir J, 58 (4) 2004605; 10.1183/13993003.04605-2020
Year: 2021



The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma
Source: International Congress 2017 – Bronchial asthma management
Year: 2017


Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007



Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients
Source: International Congress 2019 – Inhalers: adherence and preference
Year: 2019


Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE)
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008

The contribution of comorbidities, psychosocial factors and adherence to the presentation of severe asthma
Source: Eur Respir Monogr 2019; 84: 30-47
Year: 2019


The clinical impact of adherence to therapy in airways disease
Source: Breathe, 17 (2) e017902; 10.1183/20734735.0039-2021
Year: 2021



The impact of COVID-19 on patients with asthma
Source: Eur Respir J, 57 (3) 2003142; 10.1183/13993003.03142-2020
Year: 2021



Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018

Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

Associations between clinical, laboratory and therapeutical parameters on admission and adverse outcomes in patients hospitalized for COPD exacerbations
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010


Acute exacerbation phenotypes of asthma and COPD: impact on clinical outcomes
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021